Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor
XTalks
FEBRUARY 27, 2024
TILs are immune cells that attack and penetrate tumors. The immune cells in both cases are then infused back into the patient. Amtagvi is approved for the treatment of unresectable or metastatic melanoma following prior treatment with a PD-1 inhibitor and a BRAF inhibitor if the tumor harbors a BRAF V600 mutation.
Let's personalize your content